Navalign LLC’s iShares Biotechnology ETF IBB Stock Holding History

Navalign LLC’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-37	Closed	-$6.21K	–	283
2025 Q4	$6.21K	Buy	+37	New	+$6.01K	﹤0.01%	373

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Navalign LLC's IBB Position: Q1 2026 in Review

Navalign LLC sold out of iShares Biotechnology ETF (IBB) in Q1 2026, closing a stake of 37 shares — an estimated $6.21K sold.

Navalign LLC first reported a position in IBB in Q4 2025 and held it in 1 quarter. The position peaked at $6.21K in Q4 2025. 921 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Navalign LLC reported no remaining iShares Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
Navalign LLC sold 37 iShares Biotechnology ETF shares in Q1 2026, an estimated $6.21K.
Navalign LLC first reported a position in iShares Biotechnology ETF in Q4 2025 and held it in 1 quarter.
Navalign LLC's iShares Biotechnology ETF position peaked at $6.21K in Q4 2025.
921 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Navalign LLC's 13F filing for Q1 2026, filed 29 Apr 2026.